Repository logo
 

Optimal risk assessment intervals for primary prevention of cardiovascular disease: a population-based two-stage landmarking study.

Accepted version
Peer-reviewed

Change log

Authors

Abstract

INTRODUCTION: The recommended assessment intervals for primary prevention of cardiovascular disease (CVD) differ in major international guidelines. We aimed to provide empirical evidence on the optimal frequency of CVD risk assessment to inform future guidelines. METHODS: We estimated the expected time to cross the 10-year CVD risk treatment threshold of 10% using extended two-stage landmarking for more than 2 million people using UK primary care electronic health records between April 2004 and May 2019 from the Clinical Practice Research Datalink GOLD Database (CPRD GOLD), which was linked to hospital admissions data from the Hospital Episodes Statistics (HES) dataset and national mortality records from the Office for National Statistics (ONS). We grouped people based on their sex, initial risk level and age, and computed various percentiles of the expected crossing times per group. Based on the percentiles, optimal assessment intervals were identified and their performance was evaluated comparing to the current recommended intervals in the UK. RESULTS: Our results showed that the expected crossing times for people with lower initial risk were much longer than those with higher initial risk. Within each initial risk group, expected time to crossing the risk treatment thresholds was shorter in people aged ≥65 years. Based on the median expected crossing times, our recommended intervals for women with initial 10-year risk of 7.5%-10%, 5%-7.5%, 2.5%-5% or<2.5% are 3 (1 if ≥65 years old), 7 (4), 10 (6) and 10 (10) years, respectively; intervals for men are 2 (1), 5 (5), 9 (9) and 10 (10) years. These intervals outperformed the 5-yearly risk reassessment for all individuals currently recommended in the UK. CONCLUSIONS: Our evidence suggests that CVD risk assessment intervals for primary prevention should be stratified by sex, initial risk level and age. For the UK population, our method found risk assessment intervals that reduce the number of assessments required while shortening the waiting time to the next assessment for those most in need.

Description

Journal Title

BMJ Public Health

Conference Name

Journal ISSN

2753-4294
2753-4294

Volume Title

Publisher

BMJ

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
MRC (unknown)
Medical Research Council (MR/K014811/1)
British Heart Foundation (CH/12/2/29428)
British Heart Foundation (RE/18/1/34212)
British Heart Foundation (RG/18/13/33946)
National Institute for Health and Care Research (IS-BRC-1215-20014)
ZG and JKB were funded by MRC unit programme number MC_UU_00002/5, and MRC theme number MC_UU_00040/02 (Precision Medicine). FG was funded by MRC unit programme number MC_UU_00002/5. EP was supported by a Future Leader Fellowship (107210) from the National Heart Foundation of Australia. KP is supported by a New Zealand Heart Foundation Heart Health Research Trust senior fellowship (1886). J U-S was funded by an NIHR Advanced Fellowship (NIHR300861) [*]. M.A. was funded by a British Heart Foundation Programme Grant (RG/18/13/33946). D.S. was funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215- 20014). AMW was supported by the BHF Data Science Centre (HDRUK2023.0239), as an NIHR Research Professor (NIHR303137) and by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). This work was supported by core funding from the: British Heart Foundation (RG/18/13/33946), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*], Cambridge BHF Centre of Research Excellence (RE/18/1/34212), BHF Chair Award (CH/12/2/29428) and by Health Data Research UK (HDRUK2023.0028), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.